Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
840 stopped studies mapped to Malignant Prostate Neoplasm and descendants · 92% state a reason
Over the 840 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04631744 | Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Phase 2 | terminated | Nov 17, 2020 | Weill Medical College of Cornell University | Low accrual | Enrollment / accrual |
| NCT07052760 | Imaging of Solid Tumors Using DLL3 SPECT | Early Phase 1 | withdrawn | Jul 7, 2025 | Thomas Hope | Sponsor funding | Funding |
| NCT04261777 | Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients | Phase 3 | terminated | Feb 10, 2020 | Saving Patients' Lives Medical B.V. | The study was closed prematurely in order to finalise it under EU directive 2001/20/EC, without… | Other (stated, no rule matched) |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced… | Phase 2 | terminated | Oct 8, 2024 | OHSU Knight Cancer Institute | Loss of support. | Other (stated, no rule matched) |
| NCT05588609 | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers | Phase 2 | terminated | Oct 20, 2022 | Partner Therapeutics, Inc. | Merus terminated the study early due to changes in organizational priorities. | Other (stated, no rule matched) |
| NCT04984343 | Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate…(FORT) | Phase 2 | terminated | Jul 30, 2021 | Weill Medical College of Cornell University | The study was closed prematurely due to low enrollment. | Enrollment / accrual |
| NCT02555189 | Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant,… | Phase 1 / Phase 2 | terminated | Sep 21, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Sponsor-PI decision. An analysis of the primary endpoint concluded that the addition of ribociclib… | Other (stated, no rule matched) |
| NCT07541066 | Robotic Telesurgery in Urology | N/A | withdrawn | Apr 21, 2026 | Case Comprehensive Cancer Center | PI left institution | Investigator |
| NCT03869762 | Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant…(DICE) | Phase 2 | terminated | Mar 11, 2019 | Cancer Trials Ireland | Insufficient accrual | Enrollment / accrual |
| NCT04853498 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets | Phase 1 | terminated | Apr 21, 2021 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns. | Safety / toxicity |
| NCT02478112 | Use of a Biodegradable Balloon for the Treatment of Prostate Cancer by Intensity…(BioPro-RCMI) | N/A | terminated | Jun 23, 2015 | Centre Oscar Lambret | Lack of recruitment | Enrollment / accrual |
| NCT03360721 | Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic… | Phase 2 | terminated | Dec 4, 2017 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03652298 | Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative…(NeuroPrevPTSD) | Phase 2 | terminated | Aug 29, 2018 | Centre Oscar Lambret | Lack of recruitment and of study staff | Enrollment / accrual |
| NCT04179864 | A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With…(CELLO-1) | Phase 1 / Phase 2 | terminated | Nov 27, 2019 | Epizyme, Inc. | The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in… | Safety / toxicity |
| NCT02946996 | Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in… | Phase 2 | terminated | Oct 27, 2016 | Medical University of South Carolina | Investigator retired from clinical practice prior to enrollment goal being met. | Investigator |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the… | Phase 1 | terminated | Mar 1, 2024 | Deciphera Pharmaceuticals, LLC | Trial terminated due to a business decision, not based on any safety concerns. | Safety / toxicity |
| NCT04243473 | Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer | — | withdrawn | Jan 28, 2020 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study team decided to not move forward with enrolling patients because funding was not… | Enrollment / accrual |
| NCT05676463 | MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer | Phase 2 | terminated | Jan 9, 2023 | Thomas Jefferson University | Loss of required MRI resources needed to conduct protocol-specified procedures | Other (stated, no rule matched) |
| NCT00999960 | Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Simulator(PERLE) | N/A | terminated | Oct 22, 2009 | Assistance Publique - Hôpitaux de Paris | lack of inclusion | Other (stated, no rule matched) |
| NCT06047509 | Focal Laser Ablation of Prostate Cancer: A Feasibility Study Using MRI/US Image Fusion… | N/A | terminated | Sep 21, 2023 | Jonsson Comprehensive Cancer Center | low accrual | Enrollment / accrual |
| NCT05014295 | Patient Recall of Cancer Screening and Diagnosis | N/A | withdrawn | Aug 20, 2021 | Case Comprehensive Cancer Center | Staffing unavailability | Other (stated, no rule matched) |
| NCT02744287 | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With… | Phase 1 | terminated | Apr 20, 2016 | Regeneron Pharmaceuticals | Due to a Dose Limiting Toxicity. | Safety / toxicity |
| NCT04876651 | The Present Study Aims to Compare Patients Who Receive the Investigational Product… | Phase 3 | terminated | May 6, 2021 | Telix Pharmaceuticals (Innovations) Pty Ltd | Telix is conducting a separate Phase 3 clinical trial - ProstACT Global NCT06520345- to expedite… | Other (stated, no rule matched) |
| NCT03027986 | Evaluation of a Postural Rehabilitation Program Based on Sensory-motor Control in Men…(PROTOMEN) | N/A | withdrawn | Jan 23, 2017 | University Hospital, Rouen | Study population didn't exist yet | Other (stated, no rule matched) |
| NCT04754425 | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | Phase 2 | terminated | Feb 15, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT02886546 | Utility of Dynamic Variables Measured by Calibrated Pulse Contour Analysis of Oesophageal… | N/A | terminated | Sep 1, 2016 | Hallym University Kangnam Sacred Heart Hospital | Study terminated due to lack of efficacy based on interim analysis | Efficacy / futility |
| NCT05366842 | Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved… | Phase 2 | terminated | May 9, 2022 | Johns Hopkins University | The sponsor was unable to produce and provide the study material (stravix) | Other (stated, no rule matched) |
| NCT01995058 | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With… | Phase 2 | terminated | Nov 26, 2013 | Exelixis | Sponsor decided to close the study prior to completion of enrollment. This was a business decision… | Safety / toxicity |
| NCT06881823 | Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants…(NeoPSMA) | Phase 1 / Phase 2 | withdrawn | Mar 18, 2025 | Novartis Pharmaceuticals | The radioligands to be evaluated showed acceptable safety but limited benefit in metastatic… | Safety / toxicity |
| NCT06347809 | DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in… | — | terminated | Apr 4, 2024 | Mayo Clinic | Closed to consolidate enrollment under another related study | Enrollment / accrual |
| NCT04176497 | PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study | Phase 2 | terminated | Nov 25, 2019 | UNC Lineberger Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT05064111 | Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy | — | suspended | Oct 1, 2021 | University of Arizona | Per PI, the project start is on suspension. | Other (stated, no rule matched) |
| NCT03274778 | Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells | N/A | withdrawn | Sep 7, 2017 | Oncology Institute of Southern Switzerland | Recruitment difficulty due to eligibility criteria. | Enrollment / accrual |
| NCT04635059 | Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer(BLAST) | Phase 2 | terminated | Nov 18, 2020 | Medical College of Wisconsin | futility and drug supplier in favor of new metastatic protocol. | Efficacy / futility |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety… | Phase 2 | terminated | Feb 25, 2022 | SOTIO Biotech AG | Due to lack of expected efficacy shown at the time of the interim analysis | Efficacy / futility |
| NCT05037500 | Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate… | Phase 1 | terminated | Sep 8, 2021 | Roswell Park Cancer Institute | PI closed study | Other (stated, no rule matched) |
| NCT05617040 | Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive… | Phase 1 / Phase 2 | terminated | Nov 15, 2022 | Barinthus Biotherapeutics | The trial was discontinued following completion of the Phase 1 portion. This discontinuation was… | Safety / toxicity |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients… | Phase 1 | terminated | Feb 23, 2022 | Nuvation Bio Inc. | The Sponsor has achieved its objectives. | Other (stated, no rule matched) |
| NCT06060587 | Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone | Phase 2 | withdrawn | Sep 29, 2023 | Northwestern University | PI left institution | Investigator |
| NCT04910425 | PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer | Phase 2 | withdrawn | Jun 2, 2021 | Northwestern University | Study aborted | Other (stated, no rule matched) |
| NCT03792841 | Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC | Phase 1 | terminated | Jan 3, 2019 | Amgen | Sponsor Decision | Sponsor / business decision |
| NCT04645810 | A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence | N/A | withdrawn | Nov 27, 2020 | University of Rochester | study stopped early, did not enroll anyone, and will not resume | Enrollment / accrual |
| NCT04616547 | Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy… | Phase 2 | terminated | Nov 5, 2020 | National Cancer Institute (NCI) | Insufficient drug supply | Drug supply |
| NCT05276492 | Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find… | Phase 1 | terminated | Mar 11, 2022 | University of Chicago | Closed by PI due to not meeting primary endpoint | Other (stated, no rule matched) |
| NCT03503097 | Genetic Testing for Men With Metastatic Prostate Cancer(GENTleMEN) | — | terminated | Apr 19, 2018 | University of Washington | Study closed to accrual before meeting enrollment goal due to end of funding. | Enrollment / accrual |
| NCT05046782 | Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With… | Phase 2 | withdrawn | Sep 16, 2021 | M.D. Anderson Cancer Center | Study withdrawn prior to full implementation due to logistical and resource-related considerations.… | Other (stated, no rule matched) |
| NCT03284346 | Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer… | N/A | terminated | Sep 15, 2017 | University of Southern California | PI left | Investigator |
| NCT06527690 | Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients…(REPRESENTATION) | Phase 2 | withdrawn | Jul 30, 2024 | Latin American Cooperative Oncology Group | The study aimed to include multiple countries in Latin America, but only Brazil was feasible,… | Enrollment / accrual |
| NCT06516510 | A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide… | Early Phase 1 | terminated | Jul 24, 2024 | Blue Earth Therapeutics Ltd | Based on data from the Interim Analysis, the study will not adequately inform the clinical… | Safety / toxicity |
| NCT06528210 | Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of… | Phase 2 | withdrawn | Jul 30, 2024 | OHSU Knight Cancer Institute | Loss of funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated May 1, 2026source: clinicaltrials